Meningococcal Group B vaccine, Trumenba, gets approval in Europe
by News Desk from Outbreak News Today on (#2R9SK)
Pfizer Inc. announced today that the European Commission (EC) has approved TRUMENBA(R) (Meningococcal Group B Vaccine) for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in individuals 10 years of age and older. Adolescents and young adults are a critical demographic for vaccination against MenB due to inherent environmental and ["]
The post Meningococcal Group B vaccine, Trumenba, gets approval in Europe appeared first on Outbreak News Today.